<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/"><channel><title>心血管出版物</title><link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;v= 2。 17.9.post6+86293ac&amp;utm_medium=rss&amp;ff=20230922141012&amp;utm_campaign=pubmed-2&amp;utm_source=Chrome&amp;fc =20230708114047<description>心血管亮点：PubMed 的最新结果</description><atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;v=2.17.9.post6+86293ac&amp;utm_medium=rss&amp;ff=20230922141012&amp;utm_campaign=pubmed-2&amp;utm_source=Chrome&amp;fc=20230708114047" rel="self"></atom:link><docs> http://www.rssboard.org/rss-specification</docs><generator> PubMed RSS 源 (2.17.9.post6+86293ac)</generator><language> zh</language><lastbuilddate> 2023 年 9 月 22 日星期五 18:10:14 +0000</lastbuilddate><pubDate> Fri, 22 Sep 2023 06:00:00 -0400</pubDate><ttl> 120</ttl><item><title> PPP1R12C 促进心房颤动中的心房收缩力减退</title><link/>https://pubmed.ncbi.nlm.nih.gov/37737016/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20230922141012&amp;v=2.17.9.post6+86293ac<description>结论：与对照组相比，AF 患者的 PPP1R12C 蛋白水平升高。小鼠中 PPP1R12C 过表达增加了 PP1c 靶向 MLC2a 并导致 MLC2a 去磷酸化，从而降低心房收缩力并增加 AF 诱导性。这些发现表明 PP1 对 MLC2a 肌节功能的调节是AF 心房收缩力的关键决定因素。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Circ Res. 2023 年 9 月 22 日。doi：10.1161/CIRCRESAHA.123.322516。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景：心房颤动 (AF) - 最常见的持续性心律失常 - 使血栓栓塞性中风风险增加 5 倍。虽然心房收缩力不足会导致 AF 中风风险，但降低肌丝收缩功能的分子机制仍不清楚。我们测试了以下假设：表达增加PPP1R12C（蛋白磷酸酶 1 调节亚基 12C）——靶向 MLC2a（心房肌球蛋白轻链 2）的 PP1（蛋白磷酸酶 1）调节亚基——导致 MLC2a 磷酸化不足，导致心房收缩力减退。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：从 AF 患者与窦性心律对照患者中分离右心耳组织。进行蛋白质印迹、免疫共沉淀和磷酸化研究，以检查 PP1c（PP1 催化亚基）-PPP1R12C 相互作用如何导致 MLC2a 去磷酸化。药理学体外研究在心房 HL-1 细胞中进行 MRCK（肌强直性营养不良激酶相关的 Cdc42 结合激酶）抑制剂 (BDP5290) 来评估 PP1 全酶对 MLC2a 的活性。在小鼠中进行心脏特异性慢病毒 PPP1R12C 过表达，以评估伴随心房细胞缩短的心房重塑测定、超声心动图和电生理学研究的 AF 诱导性。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：在人类 AF 患者中，PPP1R12C 表达比窦性心律对照增加 2 倍（ <i>P</i> =2.0×10 <sup>-</sup> <sup>2</sup> ；每组 n=12 和 12），MLC2a 磷酸化减少 >; 40%（ <i>P</i> =1.4× 10 <sup>-</sup> <sup>6</sup> ；每组 n=12 和 12）。AF 中 PPP1R12C-PP1c 结合和 PPP1R12C-MLC2a 结合显着增加（ <i>P</i>分别 =2.9×10 <sup>-2</sup>和 6.7×10 <sup>-3</sup> ；n=8 和 8使用抑制 T560-PPP1R12C 磷酸化的药物 BDP5290 的体外研究表明 PPP1R12C 与 PP1c 和 MLC2a 的结合增加以及 MLC2a 的去磷酸化。用慢病毒 PPP1R12C 载体治疗的小鼠与对照组相比左心房大小增加了 150% ( <i>P</i> =5.0×10 <sup>-</sup> <sup>6</sup> ; n=12, 8, 和 12)，心房应变和心房射血分数降低。慢病毒 PPP1R12C 载体治疗的小鼠起搏诱发的 AF 显着高于对照组 ( <i>P</i> =1.8×分别为10 <sup>-2</sup>和4.1×10 <sup>-2</sup> ；n=6、6和5）。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：与对照组相比，AF 患者的 PPP1R12C 蛋白水平升高。小鼠中 PPP1R12C 过表达增加了 PP1c 靶向 MLC2a 并导致 MLC2a 去磷酸化，从而降低心房收缩力并增加 AF 诱导性。这些发现表明 PP1 对 MLC2a 肌节功能的调节是AF 心房收缩力的关键决定因素。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37737016/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230922141012&v=2.17.9.post6+86293ac">37737016</a> | DOI： <a href=https://doi.org/10.1161/CIRCRESAHA.123.322516>10.1161/CIRCRESAHA.123.322516</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37737016</guid><pubDate> Fri, 22 Sep 2023 06:00:00 -0400</pubDate><dc:creator>斯里坎特·佩里克</dc:creator><dc:creator>弗朗西斯科·J·冈萨雷斯-冈萨雷斯</dc:creator><dc:creator>伊萨姆·阿布·塔哈</dc:creator><dc:creator>弗雷德里克·W·达门</dc:creator><dc:creator>劳林·M·汉夫特</dc:creator><dc:creator>肯·利扎马</dc:creator><dc:creator>安娜希塔·阿布纳比</dc:creator><dc:creator>安德里埃尔·E·卡波特</dc:creator><dc:creator>尤里亚娜·阿吉拉尔-桑切斯</dc:creator><dc:creator>本杰明·莱文</dc:creator><dc:creator>韩振波</dc:creator><dc:creator>阿尔温德·斯里达尔</dc:creator><dc:creator>雅各布·格兰德</dc:creator><dc:creator>乔迪·马丁</dc:creator><dc:creator>约瑟夫·G·阿卡尔</dc:creator><dc:creator>查德·M·沃伦</dc:creator><dc:creator>R约翰·索拉罗</dc:creator><dc:creator>王相庆</dc:creator><dc:creator>达乌德·达巴尔</dc:creator><dc:creator>克里·麦克唐纳</dc:creator><dc:creator>克雷格·格尔根</dc:creator><dc:creator>贝亚塔·M·沃尔斯卡</dc:creator><dc:creator>多布罗米尔·多布雷夫</dc:creator><dc:creator>桑德尔·HT·维伦斯</dc:creator><dc:creator>马克·D·麦考利</dc:creator><dc:date>2023-09-22</dc:date><dc:source>流通研究</dc:source><dc:title>PPP1R12C 促进心房颤动中的心房收缩力减退</dc:title><dc:identifier>下午：37737016</dc:identifier><dc:identifier> doi:10.1161/CIRCRESAHA.123.322516</dc:identifier></item><item><title>在 32 个低收入和中等收入国家实施全球心脏病高血压控制计划：JACC International</title><link/> https://pubmed.ncbi.nlm.nih.gov/37734459/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20230922141012&amp;v=2.17.9.post6+86293ac<description> 2017 年，世界卫生组织 (WHO) 和 Resolve to Save Lives 与各国政府和其他利益相关者合作，在 32 个低收入和中等收入国家设计、测试和扩大 WHO HEARTS 高血压服务包。绩效指标包括入组患者人数、接受治疗且血压得到控制的患者人数、错过预定随访的人数以及失访人数。到 2022 年，HEARTS 高血压控制计划... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol。2023 年 9 月 19 日：S0735-1097(23)06633-0。doi：10.1016/j.jacc.2023.08.043。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> 2017 年，世界卫生组织 (WHO) 和 Resolve to Save Lives 与各国政府和其他利益相关者合作，在 32 个低收入和中等收入国家设计、测试和扩大 WHO HEARTS 高血压服务包。绩效指标包括入组患者人数、接受治疗且血压得到控制的患者人数、错过预定随访的人数以及失访人数。到 2022 年，HEARTS 高血压控制计划已在 165,000 个初级保健机构中治疗了 1,220 万名患者高血压控制率为 38%（中位数 48%；范围 5%-86%）。在使用相同数字健康信息系统的 4 HEARTS 国家中，基于设施的控制在 48 个月内从基线时的 18% 提高到 46%。人口水平，基于人群的高血压控制中位数估计为所有高血压患者的 11.0%（范围 2.0%-34.7%）。全球心脏实施 WHO HEARTS 的经验证明了在低收入和中等收入国家初级保健机构中控制高血压的可行性。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37734459/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230922141012&v=2.17.9.post6+86293ac">37734459</a> | DOI： <a href=https://doi.org/10.1016/j.jacc.2023.08.043>10.1016/j.jacc.2023.08.043</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37734459</guid><pubDate> Thu, 21 Sep 2023 06:00:00 -0400</pubDate><dc:creator>安德鲁·E·莫兰</dc:creator><dc:creator>丽娜·古普塔</dc:creator><dc:creator>全球之心倡议合作者</dc:creator><dc:date>2023-09-21</dc:date><dc:source>美国心脏病学会杂志</dc:source><dc:title>在 32 个低收入和中等收入国家实施全球心脏病高血压控制计划：JACC International</dc:title><dc:identifier>下午:37734459</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.08.043</dc:identifier></item><item><title> Mpox 感染可防止恒河猴再次受到攻击</title><link/>https://pubmed.ncbi.nlm.nih.gov/37734373/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20230922141012&amp;v=2.17.9.post6+86293ac<description> 2022-2023 年的 MPOX 爆发涉及男男性行为者中的全球快速传播。我们通过静脉内、皮内和直肠内途径感染了 18 只恒河猴，并在所有三种感染途径后观察到了强烈的抗体和 T 细胞反应。静脉内和皮内感染后观察到许多皮肤损伤和高血浆病毒载量。皮肤损伤在感染后第 10 天达到顶峰，并在感染后第 28 天消退。第 28 天，我们重新挑战所有... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Cell</b> . 2023 年 9 月 13 日：S0092-8674(23)00911-X. doi: 10.1016/j.cell.2023.08.023. 印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> 2022-2023 年的 MPOX 爆发涉及男男性行为者中的全球快速传播。我们通过静脉内、皮内和直肠内途径感染了 18 只恒河猴，并在所有三种感染途径后观察到了强烈的抗体和 T 细胞反应。静脉内和皮内感染后观察到许多皮肤损伤和高血浆病毒载量。皮肤损伤在感染后第 10 天达到顶峰，并在感染后第 28 天消退。第 28 天，我们用 MPOX 重新攻击所有恢复期动物和 3 只初始动物。所有恢复期动物受到保护免受再次攻击。转录组学研究表明，攻击后先天反应和炎症反应上调，胶原形成和细胞外基质组织下调，以及再次攻击后 T 细胞和浆细胞反应快速激活。这些数据表明关键机制深入了解 MPOX 发病机制和免疫。这种猕猴模型应该有助于评估 MPOX 疫苗和治疗方法。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37734373/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230922141012&v=2.17.9.post6+86293ac">37734373</a> | DOI： <a href=https://doi.org/10.1016/j.cell.2023.08.023>10.1016/j.cell.2023.08.023</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37734373</guid><pubDate> Thu, 21 Sep 2023 06:00:00 -0400</pubDate><dc:creator>马利卡援助</dc:creator><dc:creator>米凯拉·夏卡</dc:creator><dc:creator>凯瑟琳·麦克马汉</dc:creator><dc:creator>大卫·霍普</dc:creator><dc:creator>刘金艳</dc:creator><dc:creator>凯瑟琳·雅各布·多兰</dc:creator><dc:creator>奥利维亚·鲍尔斯</dc:creator><dc:creator>朱莉娅·巴雷特</dc:creator><dc:creator>吴欣迪</dc:creator><dc:creator>奥黛丽·穆托尼</dc:creator><dc:creator>泰蒂亚娜·穆尔扎</dc:creator><dc:creator>汉娜·里克特</dc:creator><dc:creator>贾森·贝拉斯科</dc:creator><dc:creator>爱丽丝·张</dc:creator><dc:creator>莫娜·布尔西夸</dc:creator><dc:creator>安东尼·库克</dc:creator><dc:creator>塔季扬娜·奥列科夫</dc:creator><dc:creator>梅丽莎·汉密尔顿</dc:creator><dc:creator>洛朗·佩森特</dc:creator><dc:creator>阿莱娜·瑞安</dc:creator><dc:creator>塔米·海耶斯</dc:creator><dc:creator>阿曼达·J·马蒂诺特</dc:creator><dc:creator>迈克尔·西曼</dc:creator><dc:creator>马克·G·刘易斯</dc:creator><dc:creator>汉娜·安徒生</dc:creator><dc:creator>丹·巴鲁克</dc:creator><dc:date>2023-09-21</dc:date><dc:source>细胞</dc:source><dc:title>Mpox 感染可防止恒河猴再次受到攻击</dc:title><dc:identifier>下午:37734373</dc:identifier><dc:identifier> doi:10.1016/j.cell.2023.08.023</dc:identifier></item><item><title>宿主特征影响野生小型哺乳动物的病毒组组成和病毒传播</title><link/>https://pubmed.ncbi.nlm.nih.gov/37734372/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20230922141012&amp;v=2.17.9.post6+86293ac<description>蝙蝠、啮齿动物和鼩鼱是人类传染病最重要的动物来源，然而，它们之间病毒的进化和传播在很大程度上仍未被探索。通过对2,443个野生蝙蝠、啮齿动物的内脏和粪便样本进行宏转录组测序，和来自中国四个栖息地的鼩鼱样本，我们鉴定出 669 种病毒，其中包括 534 种新病毒，从而大大扩展了哺乳动物病毒组。我们的分析揭示了高水平的系统发育...... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Cell</b> . 2023 年 9 月 14 日：S0092-8674(23)00916-9. doi: 10.1016/j.cell.2023.08.029. 印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">蝙蝠、啮齿动物和鼩鼱是人类传染病最重要的动物来源，然而，它们之间病毒的进化和传播在很大程度上仍未被探索。通过对2,443个野生蝙蝠、啮齿动物的内脏和粪便样本进行宏转录组测序，我们从中国四个栖息地的样本和鼩鼱样本中鉴定出 669 种病毒，其中包括 534 种新病毒，从而极大地扩展了哺乳动物病毒组。我们的分析揭示了高水平的系统发育多样性，确定了跨物种病毒传播事件，阐明了病毒起源，并确定了哺乳动物宿主中的无脊椎动物病毒。宿主顺序和样本大小是影响病毒组组成和病毒溢出模式的最重要因素。鼩鼱携带的病毒丰富度很高，包括许多与多器官分布的无脊椎动物相关病毒，而啮齿类动物则携带病毒更强的宿主跳跃能力。这些数据突显了当地栖息地中哺乳动物病毒的显着多样性以及它们在新宿主中出现的能力。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37734372/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230922141012&v=2.17.9.post6+86293ac">37734372</a> | DOI： <a href=https://doi.org/10.1016/j.cell.2023.08.029>10.1016/j.cell.2023.08.029</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37734372</guid><pubDate> Thu, 21 Sep 2023 06:00:00 -0400</pubDate><dc:creator>陈艳梅</dc:creator><dc:creator>胡树建</dc:creator><dc:creator>林贤丹</dc:creator><dc:creator>田俊华</dc:creator><dc:creator>吕家新</dc:creator><dc:creator>王妙若</dc:creator><dc:creator>罗秀琪</dc:creator><dc:creator>裴媛媛</dc:creator><dc:creator>胡瑞雪</dc:creator><dc:creator>宋志刚</dc:creator><dc:creator>爱德华·C·霍姆斯</dc:creator><dc:creator>张永珍</dc:creator><dc:date>2023-09-21</dc:date><dc:source>细胞</dc:source><dc:title>宿主特征影响野生小型哺乳动物的病毒组组成和病毒传播</dc:title><dc:identifier>下午:37734372</dc:identifier><dc:identifier> doi:10.1016/j.cell.2023.08.029</dc:identifier></item><item><title>人类诱导多能干细胞来源的心肌细胞和内皮细胞的联合治疗使小鼠和非人类灵长类动物的梗塞心脏再生</title><link/>https://pubmed.ncbi.nlm.nih.gov/37732466/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20230922141012&amp;v=2.17.9.post6+86293ac<description>结论：这些结果证明了将 iPSC 衍生的 EC 和 CM 相结合用于治疗心肌梗死后心脏的协同效应，为临床转化提供了一种有前途的策略。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>流通</b>。2023 年 9 月 21 日。doi：10.1161/CIRCULATIONAHA.122.061736。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景：将人诱导多能干细胞（hiPSC）来源的心肌细胞（CM）进行细胞移植后，可以实现哺乳动物心脏的再肌化，但在临床实践中仍存在一些障碍。血管形成，致命性心律失常发生的可能性与未成熟 CM 的胎儿细胞样性质有关。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：我们从 3 个独立供体中生成了 3 系 hiPSC 衍生内皮细胞 (EC) 和 hiPSC-CM，并在与 EC 共培养中测试了 hiPSC-CM 肌节长度、间隙连接蛋白和钙处理能力。 hiPSC-EC 和 hiPSC-CM 联合移植对心肌梗死 NOD-SCID 小鼠（n≥4）的治疗效果。通过超声心动图评估心功能，同时使用 3 导联心电图记录心律失常事件。我们进一步使用健康非-人类灵长类动物（n = 4）注射细胞，通过组织学分析研究移植的 hiPSC-CM 的细胞植入、成熟和整合，单独或与 hiPSC-EC 一起。最后，我们测试了缺血再灌注损伤中的细胞疗法在非人类灵长类动物中（EC+CM、CM 和对照分别为 4、3 和 4）。通过超声心动图和心脏 MRI 评估心脏功能，而通过遥测心电图记录仪监测心律失常事件。细胞植入，还研究了血管生成和人体移植物的宿主-移植物整合。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：我们证明人 iPSC-EC 在体外和体内均可促进 hiPSC-CM 的成熟和功能。当与 EC 共培养时，CM 在细胞结构和功能方面表现出更成熟的表型。在小鼠模型中，共移植增强了 EC-伴随移植物血管化，促进梗死区CM的成熟，改善心肌梗死后的心功能。此外，在非人灵长类动物中，EC和CM的移植显着增强了移植物的大小和血管系统，改善了缺血再灌注后的心功能。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：这些结果证明了将 iPSC 衍生的 EC 和 CM 相结合用于治疗心肌梗死后心脏的协同效应，为临床转化提供了一种有前途的策略。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37732466/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230922141012&v=2.17.9.post6+86293ac">37732466</a> | DOI： <a href=https://doi.org/10.1161/CIRCULATIONAHA.122.061736>10.1161 / CIRCULATIONAHA.122.061736</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37732466</guid><pubDate> Thu, 21 Sep 2023 06:00:00 -0400</pubDate><dc:creator>郑育哲</dc:creator><dc:creator>谢家文</dc:creator><dc:creator>林珍菊</dc:creator><dc:creator>张敏迪</dc:creator><dc:creator>黄静英</dc:creator><dc:creator>莱利·庞特尼</dc:creator><dc:creator>艾米吴梅</dc:creator><dc:creator>丁建宇</dc:creator><dc:creator>郑达连 陈先生</dc:creator><dc:creator>马丁·W·尼科尔森</dc:creator><dc:creator>林宝如</dc:creator><dc:creator>陈鸿志</dc:creator><dc:creator>吉娜·C·金</dc:creator><dc:creator>张建华</dc:creator><dc:creator>詹妮弗·库南</dc:creator><dc:creator>普加巴苏</dc:creator><dc:creator>希瑟·西蒙斯</dc:creator><dc:creator>刘彦文</dc:creator><dc:creator>蒂莫西·黑客</dc:creator><dc:creator>蒂莫西·坎普</dc:creator><dc:creator>谢长荣</dc:creator><dc:date>2023-09-21</dc:date><dc:source>循环</dc:source><dc:title>人类诱导多能干细胞来源的心肌细胞和内皮细胞的联合治疗使小鼠和非人类灵长类动物的梗塞心脏再生</dc:title><dc:identifier>下午：37732466</dc:identifier><dc:identifier> doi:10.1161/循环AHA.122.061736</dc:identifier></item><item><title> LAAOS III 中口服抗凝药的使用和左心耳封堵术</title><link/>https://pubmed.ncbi.nlm.nih.gov/37732457/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20230922141012&amp;v=2.17.9.post6+86293ac<description>结论：无论患者是否接受 OAC，左心耳封堵术的益处都是一致的。左心耳封堵术可以减少患者的血栓栓塞，而与是否使用 OAC 无关。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>流通</b>。2023 年 9 月 21 日。doi：10.1161/CIRCULATIONAHA.122.060315。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景：LAAOS III（左心耳封堵研究 III）表明，左心耳 (LAA) 封堵会增加接受心脏手术的心房颤动患者发生缺血性卒中或全身性栓塞的风险。本文根据左心耳 (LAA) 封堵对减少卒中的影响进行了研究。口服抗凝剂（OAC）使用的变化。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：在每次随访时收集有关 OAC 使用的信息。调整比例风险模型，包括使用随机化后 1 和 2 年的出院标志，评估左心耳封堵对缺血性中风或全身性栓塞风险的影响，根据整个研究中 OAC 的使用情况，还进行了调整比例风险模型，以 OAC 的使用作为时间依赖性协变量，以评估左心耳封堵的效果。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：出院时，3027 名患者（63.5%）正在接受维生素 K 拮抗剂治疗，879 名患者（18.5%）正在接受非维生素 K 拮抗剂口服抗凝剂（直接 OAC），治疗组之间 OAC 使用情况没有差异。有 2887 名（60.5%）名患者在所有随访中都接受了 OAC，1401 名（29.4%）名患者在某些访视中接受了 OAC，472 名（9.9%）名从未接受过 OAC。所有 3 组出院后缺血性卒中或全身性栓塞均一致：风险比分别为 0.70 (95% CI, 0.51-0.96)、0.63 (95% CI, 0.43-0.94) 和 0.76 (95% CI, 0.32-1.79)以 OAC 作为时间依赖性协变量的调整比例风险模型表明，无论患者是否接受 OAC，左心耳封堵术对卒中或全身性栓塞的减少程度相似。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：无论患者是否接受 OAC，左心耳封堵术的益处都是一致的。左心耳封堵术可以减少患者的血栓栓塞，而与是否使用 OAC 无关。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37732457/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230922141012&v=2.17.9.post6+86293ac">37732457</a> | DOI： <a href=https://doi.org/10.1161/CIRCULATIONAHA.122.060315>10.1161/循环AHA.122.060315</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37732457</guid><pubDate> Thu, 21 Sep 2023 06:00:00 -0400</pubDate><dc:creator>斯图尔特·J·康诺利</dc:creator><dc:creator>杰夫·希利</dc:creator><dc:creator>埃米莉·P·贝利-科特</dc:creator><dc:creator>库马尔·巴拉苏布拉曼尼安</dc:creator><dc:creator>多梅尼科·帕帕雷拉</dc:creator><dc:creator>凯瑟琳·布雷迪</dc:creator><dc:creator>威尔科·雷恩茨</dc:creator><dc:creator>伯恩哈德·C·丹纳</dc:creator><dc:creator>P·J·德弗罗</dc:creator><dc:creator>穆库尔·夏尔马</dc:creator><dc:creator>钦塔尼·拉马桑达赫蒂格</dc:creator><dc:creator>萨利姆·优素福</dc:creator><dc:creator>理查德·P·惠特洛克</dc:creator><dc:date>2023-09-21</dc:date><dc:source>循环</dc:source><dc:title>LAAOS III 中口服抗凝药的使用和左心耳封堵术</dc:title><dc:identifier>下午：37732457</dc:identifier><dc:identifier> doi:10.1161/循环AHA.122.060315</dc:identifier></item><item><title>现有的非门控 CT 冠状动脉钙可预测接受非心脏手术的患者的手术风险 (ENCORES)</title><link/> https://pubmed.ncbi.nlm.nih.gov/37732454/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20230922141012&amp;v=2.17.9.post6+86293ac<description>结论：从现有非门控胸部 CT 成像获得的冠状动脉钙化的患病率和严重程度改善了非门控手术前的术前临床风险分层。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>流通</b>。2023 年 9 月 21 日。doi：10.1161/CIRCULATIONAHA.123.064398。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景：非心脏手术前的术前心血管风险分层是一个常见的临床挑战。心电门控胸部计算机断层扫描 (CT) 成像的冠状动脉钙化评分与围手术期事件相关。在术前评估时，许多患者不会进行心电图检查门控胸部 CT 成像，但将对各种非心脏适应症进行非门控胸部 CT 研究。我们评估了根据之前的非门控胸部 CT 成像估计的冠状动脉钙化严重程度与非心脏手术后围手术期主要临床事件 (MCE) 之间的关系。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：我们回顾性地确定了 2016 年至 2020 年在由 4 个急症护理中心组成的大型学术医疗系统中接受过院内大型非门控手术的连续成年人，年龄≥45 岁。所有患者均进行了非门控（造影或非造影）胸部 CT 成像术前 1 年内，由不了解临床数据的医生使用 0 至 3 级（缺如、轻度、中度、重度）对每根血管中的冠状动脉钙从缺如到重度进行回顾性分级。计算估计的冠状动脉钙负荷 (ECCB)作为每条冠状动脉的评分总和（0 至 9 级）。计算每位患者的修订心脏风险指数。围手术期 MCE 定义为手术后 30 天内的全因死亡或心肌梗死。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：共纳入 2554 名患者（中位年龄 68 岁；49.7% 女性；中位修订心脏风险指数为 1）。从非门控胸部 CT 成像到非门控手术的中位时间间隔为 15 天（四分位数间距，3- 106 天）。中位 ECCB 为 1（四分位距，0-3）。136 例（5.2%）患者发生围手术期 MCE。较高的 ECCB 值与围手术期 MCE 逐步增加相关（0：2.9%，1- 2：3.7%，3-5：8.0%；6-9：12.6%， <i>P</i> &lt;0.001）。将 ECCB 添加到具有修订的心脏风险指数的模型中，改善了 MCE 的 C 统计量（从 0.675 到 0.712， <i>P</i> =0.018 ），净重分类改善为 0.428（95% CI，0.254-0.601， <i>P</i> &lt;0.0001）。ECCB ≥3 与 ECCB &lt;3 相比，MCE 调整后赔率高出 2 倍（调整后赔率， 2.11 [ 95% CI，1.42-3.12]）。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：从现有非门控胸部 CT 成像获得的冠状动脉钙化的患病率和严重程度改善了非门控手术前的术前临床风险分层。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37732454/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230922141012&v=2.17.9.post6+86293ac">37732454</a> | DOI： <a href=https://doi.org/10.1161/CIRCULATIONAHA.123.064398>10.1161/循环AHA.123.064398</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37732454</guid><pubDate> Thu, 21 Sep 2023 06:00:00 -0400</pubDate><dc:creator>丹尼尔·Y·崔</dc:creator><dc:creator>德纳·海耶斯</dc:creator><dc:creator>塞缪尔·梅德曼</dc:creator><dc:creator>内哈尔·达杜克</dc:creator><dc:creator>吉尔·雅各布斯</dc:creator><dc:creator>安娜·施穆克勒</dc:creator><dc:creator>杰弗里·S·伯杰</dc:creator><dc:creator>杰曼袖口</dc:creator><dc:creator>大卫·雷赫</dc:creator><dc:creator>米切尔·李</dc:creator><dc:creator>罗伯特·唐尼诺</dc:creator><dc:creator>纳撒尼尔·R·斯米洛维茨</dc:creator><dc:date>2023-09-21</dc:date><dc:source>循环</dc:source><dc:title>现有的非门控 CT 冠状动脉钙可预测接受非心脏手术的患者的手术风险 (ENCORES)</dc:title><dc:identifier>下午:37732454</dc:identifier><dc:identifier> doi:10.1161/循环AHA.123.064398</dc:identifier></item><item><title>当代心脏肿瘤学中的心血管成像：美国心脏协会的科学声明</title><link/>https://pubmed.ncbi.nlm.nih.gov/37732422/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20230922141012&amp;v=2.17.9.post6+86293ac<description>癌症治疗的进步极大地提高了患者的生存率，目前已包括近 2000 万患者，并且还在不断增加。然而，与特定癌症治疗相关的心血管毒性会对癌症患者的预后产生不利影响。心血管成像的进步巩固了癌症患者生存率的关键作用。检测、监测和预测癌症患者心脏风险的稳健方法。然而，分散的评估导致缺乏…… </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>流通</b>。2023 年 9 月 21 日。doi：10.1161/CIR.0000000000001174。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">癌症治疗的进步极大地提高了患者的生存率，目前已包括近 2000 万患者，并且还在不断增加。然而，与特定癌症治疗相关的心血管毒性会对癌症患者的预后产生不利影响。心血管成像的进步巩固了癌症患者生存率的关键作用。检测、监测和预测癌症患者心脏风险的稳健方法。然而，分散的评估导致对当代癌症治疗（例如免疫治疗、靶向治疗或生物治疗）中影像学的最佳使用缺乏共识。同样，现有的孤立的临床前和临床研究对心血管成像在癌症护理中多种模式的有效性提供了不完整的见解。本科学声明的目的是确定心血管成像在癌症治疗和生存环境中的证据的当前状态，以及提出新颖的最佳方法学方法，为心血管成像在未来临床试验和注册中的应用提供信息。我们还提出了一种基于证据的综合方法，在常规临床环境中使用心血管成像。这份科学声明总结并澄清了现有证据，同时提供新兴抗癌疗法时代多模态心血管成像的最佳使用指南。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37732422/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230922141012&v=2.17.9.post6+86293ac">37732422</a> | DOI： <a href=https://doi.org/10.1161/CIR.0000000000001174>10.1161/CIR.0000000000001174</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37732422</guid><pubDate> Thu, 21 Sep 2023 06:00:00 -0400</pubDate><dc:creator>丹尼尔·艾迪生</dc:creator><dc:creator>托马斯·内兰</dc:creator><dc:creator>安娜巴拉克</dc:creator><dc:creator>玛丽埃尔·谢勒-克罗斯比</dc:creator><dc:creator>托奇·M·奥库萨</dc:creator><dc:creator>胡安·C·普拉纳</dc:creator><dc:creator>克里恩·W·雷丁</dc:creator><dc:creator>维维安尼·R·塔奎蒂</dc:creator><dc:creator>埃里克·杨</dc:creator><dc:creator>弗拉德·G·扎哈</dc:creator><dc:creator>美国心脏协会心血管放射学和干预委员会；临床心脏病学委员会心脏肿瘤学委员会和基因组与精准医学委员会；以及心血管和中风护理委员会</dc:creator><dc:date>2023-09-21</dc:date><dc:source>循环</dc:source><dc:title>当代心脏肿瘤学中的心血管成像：美国心脏协会的科学声明</dc:title><dc:identifier>下午：37732422</dc:identifier><dc:identifier>号码：10.1161/CIR.0000000000001174</dc:identifier></item><item><title> CHIP 在 HF 中的作用：预后作用和细胞内在效应</title><link/>https://pubmed.ncbi.nlm.nih.gov/37730906/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20230922141012&amp;v=2.17.9.post6+86293ac<description>无摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Nat Rev Cardiol。2023 年 9 月 20 日。doi：10.1038/s41569-023-00942-7。印刷前在线。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37730906/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230922141012&v=2.17.9.post6+86293ac">37730906</a> | DOI： <a href=https://doi.org/10.1038/s41569-023-00942-7>10.1038/s41569-023-00942-7</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37730906</guid><pubDate> Thu, 21 Sep 2023 06:00:00 -0400</pubDate><dc:creator>卡琳娜·黄</dc:creator><dc:date>2023-09-21</dc:date><dc:source> 《自然》评论、心脏病学</dc:source><dc:title>CHIP 在 HF 中的作用：预后作用和细胞内在效应</dc:title><dc:identifier>下午：37730906</dc:identifier><dc:identifier> doi:10.1038/s41569-023-00942-7</dc:identifier></item><item><title>答复：乙酰唑胺治疗急性失代偿性心力衰竭</title><link/>https://pubmed.ncbi.nlm.nih.gov/37730297/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20230922141012&amp;v=2.17.9.post6+86293ac<description>无摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol.2023 年 9 月 26 日；82(13):e113.doi:10.1016/j.jacc.2023.07.016。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37730297/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230922141012&v=2.17.9.post6+86293ac">37730297</a> | DOI： <a href=https://doi.org/10.1016/j.jacc.2023.07.016>10.1016/j.jacc.2023.07.016</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37730297</guid><pubDate> Wed, 20 Sep 2023 06:00:00 -0400</pubDate><dc:creator>弗雷德里克·H·韦尔布鲁格</dc:creator><dc:creator>彼得·马滕斯</dc:creator><dc:creator>威尔弗里德·穆伦斯</dc:creator><dc:date>2023-09-20</dc:date><dc:source>美国心脏病学会杂志</dc:source><dc:title>答复：乙酰唑胺治疗急性失代偿性心力衰竭</dc:title><dc:identifier>下午:37730297</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.07.016</dc:identifier></item><item><title>乙酰唑胺治疗急性失代偿性心力衰竭</title><link/>https://pubmed.ncbi.nlm.nih.gov/37730296/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20230922141012&amp;v=2.17.9.post6+86293ac<description>无摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol.2023 年 9 月 26 日；82(13):e111.doi:10.1016/j.jacc.2023.06.048。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37730296/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230922141012&v=2.17.9.post6+86293ac">37730296</a> | DOI： <a href=https://doi.org/10.1016/j.jacc.2023.06.048>10.1016/j.jacc.2023.06.048</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37730296</guid><pubDate> Wed, 20 Sep 2023 06:00:00 -0400</pubDate><dc:creator>拉姆达斯·G·派</dc:creator><dc:date>2023-09-20</dc:date><dc:source>美国心脏病学会杂志</dc:source><dc:title>乙酰唑胺治疗急性失代偿性心力衰竭</dc:title><dc:identifier>下午:37730296</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.06.048</dc:identifier></item><item><title>社会经济背景对幼儿期心血管健康促进的影响</title><link/>https://pubmed.ncbi.nlm.nih.gov/37730295/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20230922141012&amp;v=2.17.9.post6+86293ac<description>无摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol.2023 年 9 月 26 日；82(13):1377-1379.doi:10.1016/j.jacc.2023.07.014。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37730295/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230922141012&v=2.17.9.post6+86293ac">37730295</a> | DOI： <a href=https://doi.org/10.1016/j.jacc.2023.07.014>10.1016/j.jacc.2023.07.014</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37730295</guid><pubDate> Wed, 20 Sep 2023 06:00:00 -0400</pubDate><dc:creator>阿玛亚·德·科斯-甘多伊</dc:creator><dc:creator>格洛丽亚·桑托斯·贝尼特</dc:creator><dc:creator>帕特里夏·博德加</dc:creator><dc:creator>豪尔赫·巴克斯特</dc:creator><dc:creator>拉克尔·迪亚兹-穆尼奥斯</dc:creator><dc:creator>克里斯托弗·希尔</dc:creator><dc:creator>伊莎贝尔·卡瓦哈尔</dc:creator><dc:creator>卡洛斯·佩拉</dc:creator><dc:creator>罗德里戈·费尔南德斯·希门尼斯</dc:creator><dc:creator>瓦伦丁·福斯特</dc:creator><dc:date>2023-09-20</dc:date><dc:source>美国心脏病学会杂志</dc:source><dc:title>社会经济背景对幼儿期心血管健康促进的影响</dc:title><dc:identifier>下午：37730295</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.07.014</dc:identifier></item><item><title>心血管护理伦理：行动呼吁</title><link/>https://pubmed.ncbi.nlm.nih.gov/37730294/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20230922141012&amp;v=2.17.9.post6+86293ac<description>无摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol.2023 年 9 月 26 日；82(13):1373-1376.doi:10.1016/j.jacc.2023.08.004。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37730294/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230922141012&v=2.17.9.post6+86293ac">37730294</a> | DOI： <a href=https://doi.org/10.1016/j.jacc.2023.08.004>10.1016/j.jacc.2023.08.004</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37730294</guid><pubDate> Wed, 20 Sep 2023 06:00:00 -0400</pubDate><dc:creator>豪尔赫·R·阿莱格里亚</dc:creator><dc:creator>B哈德利·威尔逊</dc:creator><dc:creator>R·斯科特·赖特</dc:creator><dc:date>2023-09-20</dc:date><dc:source>美国心脏病学会杂志</dc:source><dc:title>心血管护理伦理：行动呼吁</dc:title><dc:identifier>下午:37730294</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.08.004</dc:identifier></item><item><title>评估治疗效果的广义成对比较：JACC 本周评论主题</title><link/>https://pubmed.ncbi.nlm.nih.gov/37730293/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20230922141012&amp;v=2.17.9.post6+86293ac<description>首次事件发生时间复合终点分析在评估心血管临床试验中的治疗效果方面存在众所周知的缺点，它不能充分描述治疗的临床益处，因为事件的严重程度、随时间重复的事件以及临床情况。无法考虑相关的非生存结果。广义成对比较 (GPC) 方法通过包含最能捕捉到的任何数量和类型的结果，增加了定义主要终点的灵活性...... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol.2023 年 9 月 26 日；82(13):1360-1372.doi:10.1016/j.jacc.2023.06.047。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">首次事件发生时间复合终点分析在评估心血管临床试验中的治疗效果方面存在众所周知的缺点，它不能充分描述治疗的临床益处，因为事件的严重程度、随时间重复的事件以及临床情况。不能考虑相关的非生存结局。广义配对比较 (GPC) 方法通过包括与标准护理相比最能体现治疗临床获益的任何数量和类型的结局，增加了定义主要终点的灵活性。临床上重要的结局，包括出血严重程度、干预次数和生活质量，可以很容易地整合到单一分析中。GPC 中的治疗效果可以用净治疗获益、成功几率或获胜率来表示。这篇综述为以下方面提供了指导：使用 GPC 以及选择治疗效果测量来分析和报告心血管试验。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37730293/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230922141012&v=2.17.9.post6+86293ac">37730293</a> | DOI： <a href=https://doi.org/10.1016/j.jacc.2023.06.047>10.1016/j.jacc.2023.06.047</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37730293</guid><pubDate> Wed, 20 Sep 2023 06:00:00 -0400</pubDate><dc:creator>约翰·维贝克</dc:creator><dc:creator>米凯尔·德巴克</dc:creator><dc:creator>简·韦尔夫特</dc:creator><dc:creator>塞缪尔·萨尔瓦乔</dc:creator><dc:creator>马可·瓦尔吉米利</dc:creator><dc:creator>帕斯卡·弗兰克斯</dc:creator><dc:creator>马克·比斯</dc:creator><dc:creator>埃德加·布伦纳</dc:creator><dc:date>2023-09-20</dc:date><dc:source>美国心脏病学会杂志</dc:source><dc:title>评估治疗效果的广义成对比较：JACC 本周评论主题</dc:title><dc:identifier>下午:37730293</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.06.047</dc:identifier></item><item><title>无传统可改变危险因素的患者冠状动脉粥样硬化的临床路径：JACC 最先进的综述</title><link/>https://pubmed.ncbi.nlm.nih.gov/37730292/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20230922141012&amp;v=2.17.9.post6+86293ac<description> Reducing the incidence and prevalence of standard modifiable cardiovascular risk factors (SMuRFs) is critical to tackling the global burden of coronary artery disease (CAD). However, a substantial number of individuals develop coronary atherosclerosis despite no SMuRFs. SMuRFless patients presenting with myocardial infarction have been observed to have an unexpected higher early mortality compared to their counterparts with at least 1 SMuRF. Evidence for optimal management of these patients is... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol. 2023 Sep 26;82(13):1343-1359. doi: 10.1016/j.jacc.2023.06.045.</p><p> <b>ABSTRACT</b> </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> Reducing the incidence and prevalence of standard modifiable cardiovascular risk factors (SMuRFs) is critical to tackling the global burden of coronary artery disease (CAD). However, a substantial number of individuals develop coronary atherosclerosis despite no SMuRFs. SMuRFless patients presenting with myocardial infarction have been observed to have an unexpected higher early mortality compared to their counterparts with at least 1 SMuRF. Evidence for optimal management of these patients is lacking. We assembled an international, multidisciplinary team to develop an evidence-based clinical pathway for SMuRFless CAD patients. A modified Delphi method was applied. The resulting pathway confirms underlying atherosclerosis and true SMuRFless status, ensures evidence-based secondary prevention, and considers additional tests and interventions for less typical contributors. This dedicated pathway for a previously overlooked CAD population, with an accompanying registry, aims to improve outcomes through enhanced adherence to evidence-based secondary prevention and additional diagnosis of modifiable risk factors observed.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37730292/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230922141012&v=2.17.9.post6+86293ac">37730292</a> | DOI: <a href=https://doi.org/10.1016/j.jacc.2023.06.045>10.1016/j.jacc.2023.06.045</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37730292</guid><pubDate> Wed, 20 Sep 2023 06:00:00 -0400</pubDate><dc:creator> Gemma A Figtree</dc:creator><dc:creator> Stephen T Vernon</dc:creator><dc:creator> Jason A Harmer</dc:creator><dc:creator> Michael P Gray</dc:creator><dc:creator> Clare Arnott</dc:creator><dc:creator> Eric Bachour</dc:creator><dc:creator> Giannie Barsha</dc:creator><dc:creator> David Brieger</dc:creator><dc:creator> Alex Brown</dc:creator><dc:creator> David S Celermajer</dc:creator><dc:creator> Keith M Channon</dc:creator><dc:creator> Nicholas WS Chew</dc:creator><dc:creator> James JH Chong</dc:creator><dc:creator> Clara K Chow</dc:creator><dc:creator> Peter A Cistulli</dc:creator><dc:creator> Patrick T Ellinor</dc:creator><dc:creator> Stuart M Grieve</dc:creator><dc:creator> Tomasz J Guzik</dc:creator><dc:creator> Emil Hagström</dc:creator><dc:creator> Alicia Jenkins</dc:creator><dc:creator> Garry Jennings</dc:creator><dc:creator> Anthony C Keech</dc:creator><dc:creator> Katharine A Kott</dc:creator><dc:creator> Leonard Kritharides</dc:creator><dc:creator> Mamas A Mamas</dc:creator><dc:creator> Roxana Mehran</dc:creator><dc:creator> Peter J Meikle</dc:creator><dc:creator> Pradeep Natarajan</dc:creator><dc:creator> Kazuaki Negishi</dc:creator><dc:creator> John O&#39;Sullivan</dc:creator><dc:creator> Sanjay Patel</dc:creator><dc:creator> Peter J Psaltis</dc:creator><dc:creator> Julie Redfern</dc:creator><dc:creator> Philippe G Steg</dc:creator><dc:creator> David R Sullivan</dc:creator><dc:creator> Johan Sundström</dc:creator><dc:creator> Birgit Vogel</dc:creator><dc:creator> Andrew Wilson</dc:creator><dc:creator> Dennis Wong</dc:creator><dc:creator> Deepak L Bhatt</dc:creator><dc:creator> Jason C Kovacic</dc:creator><dc:creator> Stephen J Nicholls</dc:creator><dc:creator> CRE for CAD Collaborators</dc:creator><dc:date> 2023-09-20</dc:date><dc:source> Journal of the American College of Cardiology</dc:source><dc:title> Clinical Pathway for Coronary Atherosclerosis in Patients Without Conventional Modifiable Risk Factors: JACC State-of-the-Art Review</dc:title><dc:identifier> pmid:37730292</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.06.045</dc:identifier></item><item><title> The Burden of Chronic Medication in Congenital Heart Disease Matters</title><link/> https://pubmed.ncbi.nlm.nih.gov/37730291/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230922141012&amp;v=2.17.9.post6+86293ac<description> No abstract </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol. 2023 Sep 26;82(13):1341-1342. doi: 10.1016/j.jacc.2023.07.017.</p><p> <b>NO ABSTRACT</b></p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37730291/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230922141012&v=2.17.9.post6+86293ac">37730291</a> | DOI: <a href=https://doi.org/10.1016/j.jacc.2023.07.017>10.1016/j.jacc.2023.07.017</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37730291</guid><pubDate> Wed, 20 Sep 2023 06:00:00 -0400</pubDate><dc:creator> Mary B Taylor</dc:creator><dc:date> 2023-09-20</dc:date><dc:source> Journal of the American College of Cardiology</dc:source><dc:title> The Burden of Chronic Medication in Congenital Heart Disease Matters</dc:title><dc:identifier> pmid:37730291</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.07.017</dc:identifier></item><item><title> Chronic Medication Burden After Cardiac Surgery for Pediatric Medicaid Beneficiaries</title><link/> https://pubmed.ncbi.nlm.nih.gov/37730290/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230922141012&amp;v=2.17.9.post6+86293ac<description> CONCLUSIONS: Children who undergo cardiac surgery experience high medication burden that persists throughout childhood. Understanding chronic medication use can inform clinicians (both pediatricians and subspecialists) and policymakers, and ultimately the value of care for this medically complex population. </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol. 2023 Sep 26;82(13):1331-1340. doi: 10.1016/j.jacc.2023.06.046.</p><p> <b>ABSTRACT</b> </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> BACKGROUND: Congenital heart defects are the most common and resource-intensive birth defects. As children with congenital heart defects increasingly survive beyond early childhood, it is imperative to understand longitudinal disease burden. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> OBJECTIVES: The purpose of this study was to examine chronic outpatient prescription medication use and expenditures for New York State pediatric Medicaid enrollees, comparing children who undergo cardiac surgery (cardiac enrollees) and the general pediatric population. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> METHODS: This was a retrospective cohort study of all Medicaid enrollees age &lt;18 years using the New York State Congenital Heart Surgery Collaborative for Longitudinal Outcomes and Utilization of Resources database (2006-2019). Primary outcomes were total chronic medications per person-year, enrollees per 100 person-years using ≥1 and ≥3 medications, and medication expenditures per person-year. We described and compared outcomes between cardiac enrollees and the general pediatric population. Among cardiac enrollees, multivariable regression examined associations between outcomes and clinical characteristics. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> RESULTS: We included 5,459 unique children (32,131 person-years) who underwent cardiac surgery and 4.5 million children (22 million person-years) who did not. More than 4 in 10 children who underwent cardiac surgery used ≥1 chronic medication compared with approximately 1 in 10 children who did not have cardiac surgery. Medication expenditures were 10 times higher per person-year for cardiac compared with noncardiac enrollees. Among cardiac enrollees, disease severity was associated with chronic medication use; use was highest among infants; however, nearly one-half of adolescents used ≥1 chronic medication. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> CONCLUSIONS: Children who undergo cardiac surgery experience high medication burden that persists throughout childhood. Understanding chronic medication use can inform clinicians (both pediatricians and subspecialists) and policymakers, and ultimately the value of care for this medically complex population.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37730290/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230922141012&v=2.17.9.post6+86293ac">37730290</a> | DOI: <a href=https://doi.org/10.1016/j.jacc.2023.06.046>10.1016/j.jacc.2023.06.046</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37730290</guid><pubDate> Wed, 20 Sep 2023 06:00:00 -0400</pubDate><dc:creator> Joyce L Woo</dc:creator><dc:creator> Katherine A Nash</dc:creator><dc:creator> Kacie Dragan</dc:creator><dc:creator> Sarah Crook</dc:creator><dc:creator> Matthew Neidell</dc:creator><dc:creator> Stephen Cook</dc:creator><dc:creator> Edward L Hannan</dc:creator><dc:creator> Marshall Jacobs</dc:creator><dc:creator> Andrew B Goldstone</dc:creator><dc:creator> Christopher J Petit</dc:creator><dc:creator> Robert Vincent</dc:creator><dc:creator> Kathleen Walsh-Spoonhower</dc:creator><dc:creator> Ralph Mosca</dc:creator><dc:creator> TK Susheel Kumar</dc:creator><dc:creator> Neil Devejian</dc:creator><dc:creator> Steven A Kamenir</dc:creator><dc:creator> George M Alfieris</dc:creator><dc:creator> Michael F Swartz</dc:creator><dc:creator> David Meyer</dc:creator><dc:creator> Erin A Paul</dc:creator><dc:creator> Jane W Newburger</dc:creator><dc:creator> John Billings</dc:creator><dc:creator> Matthew M Davis</dc:creator><dc:creator> Brett R Anderson</dc:creator><dc:creator> New York State Congenital Heart Surgery Collaborative for Longitudinal Outcomes and Utilization of Resources (CHS-COLOUR)</dc:creator><dc:date> 2023-09-20</dc:date><dc:source> Journal of the American College of Cardiology</dc:source><dc:title> Chronic Medication Burden After Cardiac Surgery for Pediatric Medicaid Beneficiaries</dc:title><dc:identifier> pmid:37730290</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.06.046</dc:identifier></item><item><title> Time to Routinely Measure eGFR and Albuminuria in Young and Middle-Aged Adults</title><link/> https://pubmed.ncbi.nlm.nih.gov/37730289/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230922141012&amp;v=2.17.9.post6+86293ac<description> No abstract </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol. 2023 Sep 26;82(13):1328-1330. doi: 10.1016/j.jacc.2023.07.013.</p><p> <b>NO ABSTRACT</b></p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37730289/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230922141012&v=2.17.9.post6+86293ac">37730289</a> | DOI: <a href=https://doi.org/10.1016/j.jacc.2023.07.013>10.1016/j.jacc.2023.07.013</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37730289</guid><pubDate> Wed, 20 Sep 2023 06:00:00 -0400</pubDate><dc:creator> Daniel A Duprez</dc:creator><dc:creator> David R Jacobs</dc:creator><dc:date> 2023-09-20</dc:date><dc:source> Journal of the American College of Cardiology</dc:source><dc:title> Time to Routinely Measure eGFR and Albuminuria in Young and Middle-Aged Adults</dc:title><dc:identifier> pmid:37730289</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.07.013</dc:identifier></item><item><title> Impaired Renal Function and Major Cardiovascular Events in Young Adults</title><link/> https://pubmed.ncbi.nlm.nih.gov/37730288/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230922141012&amp;v=2.17.9.post6+86293ac<description> CONCLUSIONS: In young adults, eGFR below age-expected values were associated with an elevated risk for MACE and MACE+, warranting age-appropriate risk stratification, proactive monitoring, and timely intervention. </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol. 2023 Sep 26;82(13):1316-1327. doi: 10.1016/j.jacc.2023.07.012.</p><p> <b>ABSTRACT</b> </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> BACKGROUND: Cardiovascular (CV) disease in young adults (aged 18-39 years) is on the rise. Whether subclinical reductions in kidney function (ie, estimated glomerular filtration rate [eGFR] above the current threshold for chronic kidney disease but below age-expected values) are associated with elevated CV risk is unknown. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> OBJECTIVES: The goal of this study was to examine age-specific associations of subclinical eGFR reductions in young adults with major adverse cardiovascular events (MACEs) and MACE plus heart failure (MACE+). </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> METHODS: A retrospective cohort study of 8.7 million individuals (3.6 million aged 18-39 years) was constructed using linked provincial health care data sets from Ontario, Canada (January 2008-March 2021). Cox models were used to examine the association of categorized eGFR (50-120 mL/min/1.73 m <sup>2</sup> ) with MACE (first of CV mortality, acute coronary syndrome, and ischemic stroke) and MACE+, stratified according to age (18-39, 40-49, and 50-65 years). </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> RESULTS: In the study cohort (mean age 41.3 years; mean eGFR 104.2 mL/min/1.73 m <sup>2</sup> ; median follow-up 9.2 years), a stepwise increase in the relative risk of MACE and MACE+ was observed as early as eGFR &lt;80 mL/min/1.73 m <sup>2</sup> in young adults (eg, for MACE, at eGFR 70-79 mL/min/1.73 m <sup>2</sup> , ages 18-30 years: 2.37 events per 1,000 person years [HR: 1.31; 95% CI: 1.27-1.40]; ages 40-49 years: 6.26 events per 1,000 person years [HR: 1.09; 95% CI: 1.06-1.12]; ages 50-65 years: 14.9 events per 1,000 person years [HR: 1.07; 95% CI: 1.05-1.08]). Results persisted for each MACE component and in additional analyses (stratifying according to past CV disease, accounting for albuminuria at index, and using repeated eGFR measures). </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> CONCLUSIONS: In young adults, eGFR below age-expected values were associated with an elevated risk for MACE and MACE+, warranting age-appropriate risk stratification, proactive monitoring, and timely intervention.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37730288/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230922141012&v=2.17.9.post6+86293ac">37730288</a> | DOI: <a href=https://doi.org/10.1016/j.jacc.2023.07.012>10.1016/j.jacc.2023.07.012</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37730288</guid><pubDate> Wed, 20 Sep 2023 06:00:00 -0400</pubDate><dc:creator> Junayd Hussain</dc:creator><dc:creator> Haris Imsirovic</dc:creator><dc:creator> Mark Canney</dc:creator><dc:creator> Edward G Clark</dc:creator><dc:creator> Meghan J Elliott</dc:creator><dc:creator> Pietro Ravani</dc:creator><dc:creator> Peter Tanuseputro</dc:creator><dc:creator> Ayub Akbari</dc:creator><dc:creator> Gregory L Hundemer</dc:creator><dc:creator> Tim Ramsay</dc:creator><dc:creator> Navdeep Tangri</dc:creator><dc:creator> Greg A Knoll</dc:creator><dc:creator> Manish M Sood</dc:creator><dc:date> 2023-09-20</dc:date><dc:source> Journal of the American College of Cardiology</dc:source><dc:title> Impaired Renal Function and Major Cardiovascular Events in Young Adults</dc:title><dc:identifier> pmid:37730288</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.07.012</dc:identifier></item><item><title> Perioperative Myocardial Injury/Infarction After Cardiac Surgery: The Diagnostic Criteria Need to Change</title><link/> https://pubmed.ncbi.nlm.nih.gov/37730287/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230922141012&amp;v=2.17.9.post6+86293ac<description> No abstract </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol. 2023 Sep 26;82(13):1313-1315. doi: 10.1016/j.jacc.2023.08.001.</p><p> <b>NO ABSTRACT</b></p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37730287/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230922141012&v=2.17.9.post6+86293ac">37730287</a> | DOI: <a href=https://doi.org/10.1016/j.jacc.2023.08.001>10.1016/j.jacc.2023.08.001</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37730287</guid><pubDate> Wed, 20 Sep 2023 06:00:00 -0400</pubDate><dc:creator> PJ Devereaux</dc:creator><dc:creator> Richard Whitlock</dc:creator><dc:creator> Andre Lamy</dc:creator><dc:date> 2023-09-20</dc:date><dc:source> Journal of the American College of Cardiology</dc:source><dc:title> Perioperative Myocardial Injury/Infarction After Cardiac Surgery: The Diagnostic Criteria Need to Change</dc:title><dc:identifier> pmid:37730287</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.08.001</dc:identifier></item><item><title> Association of High-Sensitivity Cardiac Troponin T With 30-Day and 5-Year Mortality After Cardiac Surgery</title><link/> https://pubmed.ncbi.nlm.nih.gov/37730286/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230922141012&amp;v=2.17.9.post6+86293ac<description> CONCLUSIONS: PMI reflected by perioperative hs-cTnT release is associated with the expected 30-day mortality but not 5-year mortality. Postoperative hs-cTnT cutoffs to identify survival-relevant PMI are higher than suggested in current definitions. </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol. 2023 Sep 26;82(13):1301-1312. doi: 10.1016/j.jacc.2023.07.011.</p><p> <b>ABSTRACT</b> </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> BACKGROUND: The relevance of perioperative myocardial injury (PMI) after cardiac surgery for 30-day mortality and long-term survival remains to be determined. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> OBJECTIVES: This study assessed the association of PMI after cardiac surgery, reflected by postoperative troponin release, with 30-day mortality and long-term survival after: 1) coronary artery bypass grafting (CABG); 2) isolated aortic valve replacement (AVR) surgery; and 3) all other cardiac surgeries. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> METHODS: A consecutive cohort of 8,292 patients undergoing cardiac surgery with serial perioperative high-sensitivity cardiac troponin T (hs-cTnT) measurements was retrospectively analyzed. The relationship between postoperative hs-cTnT release and 30-day mortality or 5-year mortality was analyzed after adjustment with EuroSCORE II using a Cox proportional hazards model. hs-cTnT thresholds for 30-day and 5-year mortality were determined for isolated CABG (32.3%), AVR (14%), and other cardiac surgery (53.8%). </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> RESULTS: High postoperative hs-cTnT levels were associated with higher 30-day mortality but not 5-year mortality. In CABG, median peak concentration of postoperative hs-cTnT was 1,044 ng/L, in AVR it was 502 ng/L, and in other cardiac surgery it was 1,110 ng/L. hs-cTnT thresholds defining mortality-associated PMI were as follows: for CABG, 2,385 ng/L (170× the upper reference limit of normal in a seemingly healthy population [URL]); for AVR, 568 ng/L (41× URL); and for other cardiac procedures, 1,873 ng/L (134× URL). hs-cTnT levels above the cutoffs resulted in an HR for 30-day mortality for CABG of 12.56 (P &lt; 0.001), for AVR of 4.44 (P = 0.004), and for other cardiac surgery of 3.97 (P &lt; 0.001). </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> CONCLUSIONS: PMI reflected by perioperative hs-cTnT release is associated with the expected 30-day mortality but not 5-year mortality. Postoperative hs-cTnT cutoffs to identify survival-relevant PMI are higher than suggested in current definitions.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37730286/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230922141012&v=2.17.9.post6+86293ac">37730286</a> | DOI: <a href=https://doi.org/10.1016/j.jacc.2023.07.011>10.1016/j.jacc.2023.07.011</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37730286</guid><pubDate> Wed, 20 Sep 2023 06:00:00 -0400</pubDate><dc:creator> Leo Pölzl</dc:creator><dc:creator> Clemens Engler</dc:creator><dc:creator> Philipp Sterzinger</dc:creator><dc:creator> Ronja Lohmann</dc:creator><dc:creator> Felix Nägele</dc:creator><dc:creator> Jakob Hirsch</dc:creator><dc:creator> Michael Graber</dc:creator><dc:creator> Jonas Eder</dc:creator><dc:creator> Sebastian Reinstadler</dc:creator><dc:creator> Nikolay Sappler</dc:creator><dc:creator> Juliane Kilo</dc:creator><dc:creator> Ivan Tancevski</dc:creator><dc:creator> Sebastian Bachmann</dc:creator><dc:creator> Hannes Abfalterer</dc:creator><dc:creator> Elfriede Ruttmann-Ulmer</dc:creator><dc:creator> Hanno Ulmer</dc:creator><dc:creator> Andrea Griesmacher</dc:creator><dc:creator> Samuel Heuts</dc:creator><dc:creator> Matthias Thielmann</dc:creator><dc:creator> Axel Bauer</dc:creator><dc:creator> Michael Grimm</dc:creator><dc:creator> Nikolaos Bonaros</dc:creator><dc:creator> Johannes Holfeld</dc:creator><dc:creator> Can Gollmann-Tepeköylü</dc:creator><dc:date> 2023-09-20</dc:date><dc:source> Journal of the American College of Cardiology</dc:source><dc:title> Association of High-Sensitivity Cardiac Troponin T With 30-Day and 5-Year Mortality After Cardiac Surgery</dc:title><dc:identifier> pmid:37730286</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.07.011</dc:identifier></item></channel></rss>